Heba Youssef: Off-Label Doesn’t Mean Off-Guidelines
Heba Youssef, Clinical Nutrition Pharmacist at Helwan General Hospital, shared a post on LinkedIn about a recent article by Adam Cuker et al., published in Blood Advances, adding:
“Off-label doesn’t mean off-guidelines.
I was following a HIT case recently, and the same question kept surfacing: do we wait and manage cautiously, or move before thrombosis has a chance to develop?
Apixaban was part of the answer – but only if we follow the protocol correctly from the very first dose.
The initial dose is 10 mg twice daily, continued for 7 days or until platelet recovery, whichever is longer. After that, we transition to the maintenance dose of 5 mg twice daily.
The part that’s easy to overlook is the switch from a non-heparin parenteral anticoagulant: if the patient has completed greater than or equal to 7 days and platelets have recovered, we can start directly at 5 mg.
But if it’s been less than 7 days, we continue 10 mg until a total of 7 days of non-heparin anticoagulation is reached, then step down.
In HIT without thrombosis, some experts favor starting at 5 mg from the outset in selected patients – a reminder that this isn’t a one-size-fits-all algorithm.
Duration isn’t fixed either: 4 weeks to 3 months for HIT without thrombosis, extending to 3-6 months when thrombosis is present (HITT).
And the lesson I keep coming back to: DOACs are not first-line in hemodynamically unstable patients or those with life- or limb-threatening thrombosis. In these situations, we start with a parenteral non-heparin anticoagulant first, then consider transitioning.
The pearl I take from every case like this: a protocol isn’t just a set of dosing numbers — it’s a complete decision map that protects the patient at every turning point.”
Title: American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
Authors: Adam Cuker, Gowthami M. Arepally, Beng H. Chong, Douglas B. Cines, Andreas Greinacher, Yves Gruel, Lori A. Linkins, Stephen B. Rodner, Sixten Selleng, Theodore E. Warkentin, Ashleigh Wex, Reem A. Mustafa, Rebecca L. Morgan, Nancy Santesso
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?